MedPath

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Phase 1
Not yet recruiting
Conditions
Metastatic Prostate Cancer
Registration Number
NCT06566989
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not yet recruiting
Sex
Male
Target Recruitment
8
Inclusion Criteria

Inclusion Criteria:<br><br> - Is a healthy male according to the assessment of the investigator<br><br> - Has a body mass index of 18.0 to 32.0 kg/m2<br><br> - Has regular bowel movements (i.e., average stool production of =1 and =3 stools per<br> day)<br><br>Exclusion Criteria:<br><br> - Has the presence or history of clinically significant allergy requiring treatment<br><br> - Has a history of adrenal insufficiency<br><br> - Has veins not suitable for multiple venipunctures/cannulation<br><br> - Has previously taken part in more than 3 radiolabeled drug studies in the last 12<br> months<br><br> - Has donated blood or plasma within the previous 3 months or lost greater than 400 mL<br> of blood

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath